MMRF ImmunoOncology in Multiple Myeloma Innovations program

Funding Agency:
Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) is pleased to announce a new Clinical and Translational research program to investigate novel, hypothesis-driven, ImmunoOncology (IO) strategies for Multiple Myeloma. Currently, the IO treatment landscape features a wide array of approved and investigational IO strategies, presenting a significant challenge of combining and sequencing these agents for the optimal clinical response in the appropriate patient populations.

The MMRF ImmunoOncology in Multiple Myeloma Innovations program RFA will support innovative, hypothesis-driven clinical trials that are paired with correlative studies designed to demonstrate mechanisms of action or resistance, biomarkers for patient selection, and identification of ancillary targets.

The MMRF encourages the submission of collaborative projects involving academic institutions and pharmaceutical industry partners.

Letter of Intent Due Date December 20, 2019

Agency Website

Eligibility Requirements

Applications for this RFA are being solicited from investigators holding a PhD, MD or equivalent
degrees with faculty appointments at MMRC affiliated academic institutions. Collaborations among
academic institutions and pharmaceutical partners are encouraged; a MMRC site must serve as the lead
institution of the clinical trial, but the translational studies may be distributed among collaborators.



Amount Description

Proposals may request funding up to $500,000 a year, including up to 10% indirect costs, for a two (2) year period.
Funds may be budgeted for up to 25% of clinical costs and up to 100% of translational costs.

Funding Type



Junior Faculty


Medical - Clinical Science
Medical - Translational

External Deadline

December 20, 2019